Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Choi; Woo-Baeg
Address:
North Brunswick, NJ
No. of patents:
22
Patents:












Patent Number Title Of Patent Date Issued
7468436 Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers December 23, 2008
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1
7402588 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane July 22, 2008
A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or N.sup.4 alkylat
7160999 Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers January 9, 2007
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1
6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers March 9, 2004
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,
6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane November 4, 2003
A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or N.sup.4 alkylat
6346627 Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers February 12, 2002
Intermediates in the synthesis of 1,3-Oxathiolane Nucleosides.
6242596 Preparation of betamethyl carbapenem intermediates June 5, 2001
A process for making a beta methyl carbapenem intermediate is disclosed. A compound of formula I: ##STR1##is contacted in a non-reactive solvent with methyl Meldrum's acid and a base to produce a compound of formula III: ##STR2##Compound III is treated in an aprotic solvent with a sc
6153751 Method and compositions for the synthesis of BCH-189 and related compounds November 28, 2000
The present invention relates to a method of preparing BCH-189 and various analogs of BCH-189 from inexpensive precursors with the option of introducing functionality as needed. This synthetic route allows the stereoselective preparation of the biologically active isomer of these com
6143885 Preparation of beta-methyl carbapenem intermediates November 7, 2000
The instant invention relates to a compound of the formula: ##STR1## wherein R.sub.a and P are: (a) hydrogen,(b) methyl, or(c) a hydroxy protecting groupand an efficient process for its synthesis characterized by combining a ketoester with an acid and a catalyst at a temperature of from
6114343 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane September 5, 2000
A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or N.sup.4 alkylat
6069252 Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers May 30, 2000
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1
5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane June 22, 1999
A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or N.sup.4 alkylat
5900368 Process for bioreduction of bisaryl ketone to bisaryl alcohol May 4, 1999
The present invention is directed to an improved process for making PDE IV inhibitors. In specific, this application describes a process for making and purifying a chiral bisaryl alcohol, an intermediate compound necessary for the preparation of PDE IV inhibitors such as CDP 840, by asym
5892025 Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers April 6, 1999
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that referentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,
5852027 Antiviral 1,3-dioxolane nucleoside analogues December 22, 1998
This invention includes the compounds 2'-deoxy-5-fluoro-3'-oxacytidine, (-)-2'-deoxy-5-fluoro-3'-oxacytidine, and (+)-2'-deoxy-5-fluoro-3+-oxacytidine, and pharmaceutically acceptable salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV inf
5827727 Method of resolution of 1,3-oxathiolane nucleoside enantiomers October 27, 1998
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1
5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related September 29, 1998
The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularl
5808082 Method of preparing phosphodiesterase IV inhibitors September 15, 1998
A process for the preparation of Phosphodiesterase IV inhibitors is described. The process consists of eight chemical steps involving five isolations to prepare the title compound from readily available isovanillin in 35% overall yield (Scheme 1). The process is highlighted by: a) a
5728575 Method of resolution of 1,3-oxathiolane nucleoside enantiomers March 17, 1998
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (-)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1
5700937 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related December 23, 1997
The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularl
5654424 Preparation of beta-methyl carbapenem intermediates August 5, 1997
The present invention is directed to a process of making a Beta-methyl carbapenem intermediate of formula VI from a compound of formula I ##STR1## wherein R and P' are protecting groups R.sup.1 is a methylmalonic acid ester and Nu is a nucleophilic group. Process intermediates are al
5210085 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related May 11, 1993
The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularl










 
 
  Recently Added Patents
Determination method for a reinitialization of a temporal sequence of fluoroscopic images of an examination region of an examination object
Method and system for evaluating/analyzing patent portfolio using patent priority approach
Organic electroluminescence element
Soybean cultivar CL1013665
Biphotonic photosensitizers, nanoparticles containing the same and their use as drugs
High density vertical structure nitride flash memory
Automatic pill dispenser
  Randomly Featured Patents
Device for scanning a radiation-reflecting information surface with optical radiation
Floating lens mounting system
Solid discharge mechanism for dewatering system
Transistor provided with strained germanium layer
Apparatus and method for detecting missing or defective battery conditions
Liquid crystal display panel and method for manufacturing thereof and liquid crystal display incorporating the same
Nucleic acid sequence for potentiating the expression of useful gene and method therefor
Golf putting training and practice aid
Magnetic crash sensor
Modular planter panel system